* Individual results may vary.
RenovoRx Announces Studies that Further Advance the Science of Pancreatic Cancer Treatment Presented at the 2021 ASCO Gastrointestinal Cancers Symposium
RenovoRx Continues with Strong Momentum and Reaches Milestone of 100th Patient Enrolled in its Phase III TIGeR-PaC Clinical Trial
Parexel Biotech and RenovoRx Reach Key Milestone in Pancreatic Cancer Clinical Trial for Locally-Advanced Pancreatic Cancer
70-year old patient, Mrs. Darlene Bossolla, was diagnosed with inoperable pancreatic cancer last year. Now, part of the TIGeR-PaC clinical trial at UPMC with Dr. Paula Novelli, Mrs. Bossola is reporting her levels to be down and she is feeling great and that she believes this new procedure should be available to everyone.
Based on results of early studies highlighted by this patient’s and other patients’ experiences, RenovoRx initiated and is currently enrolling Stage 3 pancreatic cancer patients in the TIGeR-PaC clinical trial to further test this promising new procedure for pancreatic cancer patients.
Researchers Report Survival Benefits with Use of RenovoCath™ in Patients with Locally Advanced Pancreatic Tumors
Presentation of Data on Intra-arterial Targeted Delivery of Gemcitabine in Treatment of Loco-regional Pancreatic Tumors
RenovoRx’s Board Member Dr. Laurence (Larry) J. Marton, MD is a leading expert with extensive experience in the fields of drug development, with a focus on treating human diseases related to cell growth including cancer.
RenovoRx has been selected for the 10th Annual BayBio Entrepreneur and Investor Roundtables to be held on February 14, 2013 in San Francisco.